STAT
JUNE 24, 2025
Today, we talk about the readout of Compass Pathways’ psilocybin trial for major depressive disorder, see more vaccine concern and turnover at the FDA, and report from the American Diabetes Association.
Pharmafile
JULY 10, 2025
Amarna Therapeutics and NorthX Biologics have finalised an agreement to accelerate the development of Nimvec AM510, a gene therapy targeting immune-mediated diseases, with an initial focus on type 1 diabetes (T1D). The collaboration aims to establish robust, scalable manufacturing processes and support clinical trial preparation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
JULY 8, 2025
You just want to slash it, rip it out or attack it like an enemy target,” said Benjamin Zeskind, co-founder, CEO and president of Immuneering Corporation. To overcome that hurdle, Immuneering is testing an approach that slows cancer down rather than rushing to destroy it. I think we have to control cancer before we cure it.”
Pharmacy Times
JULY 16, 2025
That was the question on the minds of a lot of health care professionals, public policy leaders, public health officials, and select politicians going into the first meeting of the new Advisory Committee on Immunization Practices (ACIP) in June 2025. Editor's Footnote In May 2025, Secretary Robert F. Kennedy Jr.
Pharmacy Times
JULY 12, 2025
Innovative pharmacist-led care models—from tech-enabled Afib screenings and HPV immunizations to Medicare-supported diabetes prevention—demonstrate how pharmacies are redefining their role in team-based clinical care.
Pharmacy Times
JUNE 24, 2025
Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)
Pharmacy Times
JUNE 20, 2025
Prior to October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a PCV only for all adults aged 65 years and older, including those aged 19 to 64 years with risk conditions for pneumococcal disease. Kobayashi M, Leidner AJ, Gierke R, et al. MMWR Morb Wkly Rep. 2025;74:1-8. doi:10.15585/mmwr.mm7401a1 3.
Expert insights. Personalized for you.
231 
Let's personalize your content